Creative Biolabs is strengthening its lipid-based delivery portfolio with enhanced lipid nanoparticle (LNP) and liposome engineering capabilities designed to support the growing demand for RNA ...
Through predictive modelling, AI supports target identification, prediction of physicochemical properties and formulation strategy selection.
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphereâ„¢ technology designed to optimize ...
Henny Zijlstra, Chief Commercial Officer of Ardena, discusses the integrated CDMO model, Ardena’s new laboratory in New ...
The U.S. Lipid Nanoparticle CDMO Market is projected to reach USD 0.44 billion by 2035, while Europe is expected to reach USD 0.27 billion, driven by expanding mRNA, siRNA, gene-editing therapeutics, ...
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging ...
When life sciences startups think about patent strategy, the natural instinct is to focus on the core science — the novel compound, the ...
PALO ALTO, Calif.--(BUSINESS WIRE)--GEn1E Lifesciences Inc., a Phase 2 clinical-stage biotechnology company advancing AI-driven novel precision medicines for immunology, inflammation, and rare ...
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of ...
NITI Aayog study asks Ayurveda industry to bring in clarity on patents in Ayurveda: Gireesh Babu, New Delhi Wednesday, July 8, 2026, 08:00 Hrs [IST] In order to take the Ayurveda ...
VANCOUVER, BC / ACCESS Newswire / July 6, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...
The Multidisciplinary Committee (MDC) has sought additional documentary evidence from G.S. Pharmbutor Private Limited to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results